World Wires · story 12496 · unverified · 1 source(s)

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat

Open in the desk

Coverage

• Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026 GlobeNewswire: public companies · tier D · clear net · 2026-10-01 10:45 UTC

What this site indexes